Jun 1, 2026 · 2h 48m
Clinicians warn of sourcing risks amid the rapid rise of peptide therapeutics
Peptides: The Science, Uses & Safety | Dr. Abud Bakri
As peptides gain mainstream popularity for healing and longevity, understanding the science and safety risks is crucial to avoiding contaminated products and ineffective treatments.
- 1Sourcing safety and regulatory compliance are critical when navigating the rapidly evolving peptide market.
- 2Compounds like BPC-157 and GLP-1 agonists show therapeutic promise but require careful clinical oversight.
- 3Bridging the gap between animal data and human trials is essential for safe peptide adoption.
Don't miss
Dr. Abud Bakri details the therapeutic potential and regulatory hurdles of tissue-repairing compounds like BPC-157.
The brief
Peptides are transforming modern medicine, offering targeted interventions for tissue repair, metabolic dysfunction, and longevity, yet their rapid rise has outpaced regulatory frameworks and robust human clinical trials.
Dr. Abud Bakri explains that while compounds like BPC-157 and GLP-1 agonists show immense clinical promise, the lack of human data means patients must navigate a landscape filled with sourcing risks and unverified claims.
The gap between promising animal data and verified human outcomes remains a critical hurdle, making rigorous clinical oversight and safe sourcing paramount for anyone exploring peptide therapeutics.
Ultimately, peptides represent a shift toward highly specific medicine, but unlocking their potential to treat neurological and immune decline safely requires bridging the gap between biohacking and clinical science.
What was said on this episode
74 statements · 44 positive · 14 negative · 4 mixed · 12 neutral
People combine GLP-1, growth-hormone, and androgen therapies to transform fitness quickly.
“People are now stacking their GLP1 as their insulin sensitivity tool, their growth hormone or their GHRH and their androgen modulation therapies as this trinity stack.”
Listen at 0:00
Peptides are a biological communication language between human cells.
“peptides are one of these languages”
Listen at 4:34
GLP-1 peptides have stronger clinical effects than obscure peptides lacking clear targets.
“the GLP1s, which have a very strong clinical effect compared to these obscure peptides like BBC157, TB500, TB4, that don't have a clear target.”
Listen at 4:46
BPC157 and TB4 currently lack identified receptors.
“We don't have a receptor identified for BBC157 or TB4.”
Listen at 4:59
Russian peptides act as epigenetic modifiers by binding DNA grooves.
“The Russian peptides are all epigenetic modifiers that they bind to the groove of the DNA”
Listen at 5:35
BPC157 is a 15-amino-acid fragment humans do not naturally produce.
“BPC157 is 15amino acids from that giant peptide. We don't naturally make BPC157.”
Listen at 7:31
BPC157 accelerated healing in multiple injured-mouse models.
“they'd have faster healing times”
Listen at 11:51
BPC157 increases VEGF signaling and blood-vessel formation in experimental models.
“You'll get more VEGF signaling. So that's the vascular endothelial growth factor. So get more blood vessels androgenesis being formed”
Listen at 16:28
BPC157 preserved or improved wound healing despite corticosteroid treatment in mice.
“When BPC was administered, the healing was either the same or even better.”
Listen at 17:01
BPC157 prevented alcohol-withdrawal symptoms in an animal model.
“they got BPC and they didn't have the withdrawal symptoms.”
Listen at 18:42
Some users report oral BPC157 blunts Adderall effects.
“it seems like it's blunting their Adderall”
Listen at 19:06
Animals tolerated BPC157 doses up to approximately 1,000 times typical doses.
“they've injected animals with, you know, a thousand times the dose of BPC with no real adverse effects.”
Listen at 20:13
Two small early trials evaluated rectal BPC157 enemas in humans.
“There was two very small phase 1 and phase 2 trials on rectal BPC enemas in the early 2000s”
Listen at 20:47
A small phase-one trial reported no adverse effects from rectal BPC157.
“The first, the phase one trial showed no adverse effects”
Listen at 21:44
Oral and rectal BPC157 appears not to enter systemic circulation.
“orally administered or rectally administered BPC doesn't seem to go systemic.”
Listen at 21:52
A small phase-two trial found a positive ulcerative-colitis signal for BPC157.
“in the phase 2 trial, it was very small, like 40 patients. There was at least a positive signal on the ulcerative colitis.”
Listen at 23:13
U.S. gray-market peptide spending was estimated at $5–10 billion in 2025.
“there's Maybe I'd say 5 to 10 billion dollars on gray market peptides being spent in the United States in 2025.”
Listen at 34:19
Active pharmaceutical ingredients for these peptides primarily come from China.
“The API for all these active pharmaceutical ingredients comes from China.”
Listen at 35:29
Some compounding pharmacies provide strong testing, sterility, and quality control.
“Some of them are really good. They do all the testing, sterility. They have very good quality control. So you get a good product”
Listen at 36:22
Research-market peptides vary widely and may contain the wrong substance.
“The research stuff is all over the place. Like, some of it could be better than compounded stuff. It could be the wrong substance.”
Listen at 37:00
Animal studies have not shown a cancer signal for BPC157.
“There is no signal from the Animal Literature on BPC157 for, you know, cancers.”
Listen at 43:03
Some users report worsening hematomas with BPC157, consistent with VEGF effects.
“on Reddit you'll find signals of hematomas getting worse. Which makes sense with the, with the VEGF pathway.”
Listen at 44:05
BPC157 could potentially treat gastric ulcers in intensive-care patients, pending evidence.
“if we knew that it would work, I would love to give them an infusion of BPC157.”
Listen at 45:11
Researchers should conduct a phase-three BPC157 trial for ulcerative colitis.
“I would say to complete the phase one, phase two on the ulcerative colitis, do that phase three trial on proving that it has benefits for ulcerative colitis.”
Listen at 50:06
BPC157 might shorten post-surgical ACL recovery from twelve months to six.
“can it further accelerate the healing from an ACL surgery so you come back in six months rather than 12 months? That's the big question.”
Listen at 53:29
BPC157 may be highly beneficial, ineffective, or harmful; current data cannot distinguish these outcomes.
“Either BPC is as amazing as we think it is and it's unfortunate that millions of people don't have access to it, or BBC is actually either ineffective or harmful to people”
Listen at 57:37
Some dipeptides and tripeptides can be orally bioavailable depending on structure.
“Dye and tripeptides can be orally available if they're the right shape and size.”
Listen at 1:03:49
Epitalon restored melatonin production in aged animals and was later replicated in humans.
“He was able to restore melatonin production in these aged animals and eventually replicated on humans.”
Listen at 1:11:55
Pinealon may improve brain metabolism by modulating multiple pathways.
“Pinealon in one sentence, it's leading to better brain metabolism through modulating all these different pathways.”
Listen at 1:13:59
Pinealon preserved athletic performance after maximal training exhaustion in one study.
“The Pennylon group could keep the performance up despite being maximally exhausted from their training.”
Listen at 1:14:41
Pinealon is orally available through peptide transporters.
“It's orally available through these Latin pep transporters.”
Listen at 1:15:22
Pinealon most likely crosses the blood-brain barrier.
“Most likely, yes.”
Listen at 1:15:26
Pinealon may lower blood sugar by activating PPAR-alpha and PPAR-gamma.
“Some people have a little drop in blood sugar because it activates PPR alpha, PPR gamma”
Listen at 1:17:16
A Russian longevity study reported lower cardiovascular, infectious, and cancer mortality with peptide treatment.
“they had a significant lower mortality when it came to cardiovascular disease, infectious risk and for cancers.”
Listen at 1:24:48
Removing residual thymus tissue is associated with increased five-year mortality after surgery.
“removing the thymus tissue, residue tissue, leads to a mortality signal within the first five years after those surgeries.”
Listen at 1:30:40
A 12-month growth-hormone, metformin, and DHEA cocktail increased thymus size on imaging.
“giving a cocktail of growth hormone, metformin, and DHEA gave that for 12 months and had the thymic size increase on imaging”
Listen at 1:34:38
Thymosin alpha-1 promotes T-cell development and pathogen-targeting activity.
“It increases T cell development in the thymus, increases T cell perforation outside the thymus, and makes the T cells more likely to properly attack a pathogen.”
Listen at 1:35:28
Thymosin alpha-1 is approved as adjunctive therapy for hepatitis and some cancers abroad.
“In other countries, it's approved for a adjuvant therapy for, like, hepatitis B, hepatitis C, see, and in different cancers.”
Listen at 1:36:21
Thymosin beta-4 supports cellular actin-cytoskeleton function.
“Thymus and beta 4 seems to be this 43amino acid peptide that helps in the actin cytoskeleton of cells.”
Listen at 1:38:38
Pinealon is available over the counter in pharmacies across several countries.
“Is a, you know, penalon is a supplement you can find in Kazakhstan and Russia and Ukraine, wherever, all these different countries, over the counter in different pharmacies.”
Listen at 1:44:11
Oral Pinealon requires higher doses but remains effective, according to Bakri.
“In a capsule, higher doses is needed, but it still works.”
Listen at 1:44:22
Thymulin increased HCG-stimulated testosterone production in animal models.
“they would get more testosterone produced when they got HCG with thymulin versus HCG alone.”
Listen at 1:47:30
Thymulin has a very short biological half-life.
“Thymulin itself has a very short half life.”
Listen at 1:48:56
Adequate zinc is necessary for thymulin production.
“sufficient zinc status is necessary to make thymeulin”
Listen at 1:49:03
Adequate zinc is necessary for thymulin production.
“sufficient zinc status is necessary to make thymeulin.”
Listen at 1:49:03
GHK-Cu may regulate both collagen synthesis and collagen breakdown.
“he discovers GHKCU in the collagen tissue. And he's like, hey, this might be the factor that controls collagen synthesis and also collagen breakdown.”
Listen at 1:52:01
GHK-Cu serum levels decline substantially with age.
“So dramatically decreases with age.”
Listen at 1:52:34
Injected GHK-Cu accelerated skin wound repair in rat studies.
“they'd get faster wound repair of the, the skin tissue from injecting this”
Listen at 1:52:56
GHK-Cu upregulates both collagen synthesis and collagen breakdown.
“It both upregulates the synthesis side of collagen and the breakdown side of collagen.”
Listen at 1:53:33
GHK-Cu is not established as superior to minoxidil but may be an adjunct.
“it's not going to the peptide sites. Try to tell you, like, this is better than minoxidil. Not really. Maybe it could be an adjunct.”
Listen at 1:54:04
Every infection causes temporary thymic atrophy.
“There's thymic atrophy that happens after every infection.”
Listen at 1:55:03
Thymulin treatment improved CD4, CD8, and other immune markers in reported research.
“He showed like CD4 cells come up and CD8 cells improve and all his immune markers become a more youthful state”
Listen at 1:57:41
Thymic interventions could enhance population immunity.
“we could have used these thymic focused interventions, whether it be zinc or thymic peptides or purified thymic extracts to augment immunity of the population as a whole”
Listen at 1:58:25
Somatopause in the thirties involves a dramatic decline in growth hormone production.
“Somatopause is this event that happens somewhere in the 30s where growth hormone production dramatically decreases.”
Listen at 2:06:18
IGF-1 is proposed to support skin, sleep, muscle recovery, and joints.
“The proponents will say IGF1 is important for skin and, and good quality sleep and for muscle recovery and joints and all these things.”
Listen at 2:07:03
Growth hormone may promote growth of existing cancers.
“But is it, you know, a growth factor that could grow cancer? Potentially.”
Listen at 2:07:53
Growth-hormone-deficient models can have substantially longer lifespans.
“There's models where people are growth hormone deficient and live a lot longer”
Listen at 2:08:15
Prostate growth with age is influenced by DHT, estrogen, and possibly growth hormone.
“The prostate is growing with age under the control of DHT and estrogen and then probably growth hormone.”
Listen at 2:12:50
Injectable GHK-Cu is not FDA-approved and may face future regulatory review.
“The injectable is not FDA approved of course. I think it's going to be on the second round of discussions when it comes to the peptides.”
Listen at 2:16:36
Topical GHK-Cu has human aesthetic evidence and may work synergistically with red light.
“But topically there's great human data on like different aesthetic outcomes, especially when coupled with red light therapy because it seems that the blue pigment and the red light seem to be synergistic in that effect.”
Listen at 2:16:52
GLP-1 medications are beneficial and are transforming medicine.
“These medications are good. Trying to transforming medicine”
Listen at 2:22:15
GLP-1 drugs can reduce body weight by up to 30 percent.
“with the GLP1s, we're getting 10, 20, even 30% of body weight being shaved off of people”
Listen at 2:23:41
Some patients regain their baseline weight after stopping GLP-1 drugs.
“Some people don't, but some people will regain back to baseline.”
Listen at 2:25:49
Appropriate GLP-1 dosing may decrease brain inflammation.
“the right amount of dose decreases inflammation in the brain”
Listen at 2:29:40
GLP-1 drugs reduce alcohol cravings.
“the literature shows that people now are having less alcohol cravings from this”
Listen at 2:30:00
Weight loss can improve fertility among overweight or obese women.
“These are overweight obese women that are having their fertility improve as a result of losing the weight.”
Listen at 2:31:41
GLP-1 drugs should be titrated slowly to reduce adverse effects.
“That's why I titrate very slowly.”
Listen at 2:33:38
Retatrutide will become a trillion-dollar industry.
“I thought, and I do still think that redruetide is going to be a trillion dollar industry.”
Listen at 2:33:57
Retatrutide will likely prove useful for multiple medical indications.
“I'm guessing that retatrutide is. We're going to discover that it's useful for a number of things.”
Listen at 2:34:58
No animal or human evidence links BPC-157 to endometriosis or fibroids.
“no literature exists on either animal or human data that relates those peptides”
Listen at 2:39:44
There is no strong evidence that BPC-157 treats traumatic brain injuries.
“There's no good data on BPC and TBIs.”
Listen at 2:40:53
Peptide use should be physician-led and medically monitored.
“it should be physician led. You should be doing this under the guidance of a physician that's monitoring you.”
Listen at 2:43:42
Patients should not take tesamorelin without monitoring IGF-1 levels.
“You shouldn't be taking Testamorlin without checking IGF1 levels.”
Listen at 2:43:47
Broad physician-led peptide options will become available within six months.
“I think within six months there'll be very good physician options for everybody.”
Listen at 2:44:27
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.